News
CHMP extends the indication of Refixia to prophylaxis of bleeding in patients 12 years and above with haemophilia B
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Refixia.
The marketing authorisation holder for this medicinal product is Novo Nordisk A/S. The CHMP adopted an extension to an existing indication as follows: Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency).Refixia can be used for all age groups.
Condition: Haemophilia B
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.